Flagship's Abiologics uses AI to create proteins made from mirror-image building blocks.
Abiologics, a startup founded by the life science venture firm Flagship Pioneering, has successfully used artificial intelligence to create proteins — and potentially, more durable drugs — …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout
Alnylam will pay $30 million upfront for its first discovery-focused AI deal, tapping a Silicon Valley biotech startup to see if…
Nonprofit Blood Cancer United acquires cancer drug, Lilly and Nvidia invest in Abridge, and more biotech news
Delaware-based Incyte is now turning to AI to power through the coming decades.
CEO of BigHat Biosciences, which designs antibody therapies using machine-learning, on how AI can, and cannot, help in drug…
Alnylam announced a three-year deal with Inceptive Nucleics, worth up to $2 billion, with $30 million upfront in cash and equity…
